

ALLERGAN INC  
Form 15-12B  
March 27, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**  
**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number 1-10269**

**ALLERGAN, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Morris Corporate Center**  
**400 Interpace Parkway**  
**Parsippany, New Jersey 07054**

(862) 261-7000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock (\$0.01 par value)

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	x
Rule 12g-4(a)(2)	..
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	..
Rule 15d-6	..

Approximate number of holders of record as of the certification or notice date: One\*

\* On March 17, 2015, pursuant to the Agreement and Plan of Merger, dated November 16, 2014 among Actavis plc ( Actavis ), Avocado Acquisition Inc. ( Merger Sub ) and Allergan, Inc. (the Company ), Merger Sub merged with and into the Company, with the Company being the surviving entity (the Merger ). As a result of the Merger, the Company became an indirect wholly owned subsidiary of Actavis.

Pursuant to the requirements of the Securities Exchange Act of 1934, Allergan, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: March 27, 2015

ALLERGAN, INC.

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: President and Chairman of the Board